Previous Article | Next Article ![]()
Journal of Clinical Microbiology, February 2007, p. 294-298, Vol. 45, No. 2
0095-1137/07/$08.00+0 doi:10.1128/JCM.01694-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.
Division of Microbiology, Calgary Laboratory Services,1 Departments of Pathology & Laboratory Medicine,2 Medicine,3 Microbiology and Infectious Diseases,4 Critical Care, University of Calgary, Calgary, Alberta, Canada5
Received 16 August 2006/ Returned for modification 18 October 2006/ Accepted 8 November 2006
|
|
|---|
|
|
|---|
In the absence of novel agents for the treatment of infections caused by multiresistant gram-negative bacteria, the uncontrolled spread of MBL producers may lead to treatment failures, with increased morbidity and mortality (22). Previous studies illustrated that MBL-producing P. aeruginosa strains are an important cause of carbapenem resistance (CR) among members of this species isolated from the Calgary Health Region (CHR) (9, 14). The CHR provides all publicly funded healthcare services to the population of >1 million residing in the cities of Calgary and Airdrie, Canada, and numerous adjacent surrounding communities covering an area of 37,000 km2 (1). Acute care is provided principally through one pediatric and three large adult hospitals (acute care centers I, II, and III). A centralized laboratory (Calgary Laboratory Services [CLS]) performs all routine clinical microbiology services for both the community and hospital sites within the CHR.
Very limited data are available regarding the epidemiology of MBL-producing P. aeruginosa strains in large geographical areas. We decided to investigate the molecular epidemiology of CR P. aeruginosa strains isolated in the CHR over a 4-year period, from April 2002 to March 2006.
|
|
|---|
Antimicrobial susceptibility testing. MICs of the following drugs were determined by Vitek (Vitek AMS; bioMérieux Vitek Systems Inc., Hazelwood, MO) and microdilution panels (Microscan gram-negative NMIC30; Dade Behring Canada Inc., Mississauga, Ontario, Canada): piperacillin (PIP), ceftazidime (CAZ), aztreonam (ATM), IPM, ciprofloxacin (CIP), gentamicin (GEN), amikacin (AMK), and tobramycin (TOB). Colistin (COL) susceptibility was determined using Etest (AB BioDisk Company, Solna, Sweden). The quality control strains used for this part of the study were Escherichia coli ATCC 25922, P. aeruginosa ATCC 27853, and Staphylococcus aureus ATCC 29213. Throughout this study, results were interpreted using CLSI criteria for broth dilution (12).
Identification of metallo-ß-lactamases. The presence of MBLs was evaluated in the clinical isolates of CR P. aeruginosa by using both an EDTA screen test (14) and the MBL Etest (AB BioDisk Company, Solna, Sweden) according to the manufacturer's instructions. DNA template preparation and duplex PCR amplification for the simultaneous detection of blaIMP and blaVIM ß-lactamase genes were carried out on a Thermal Cycler 9700 instrument (Applied Biosystems, Norwalk, CT), using previously described primers and conditions (14). Sequencing of the VIM and IMP genes was performed using the class 1 integron primers 5CS (5'-GGC ATC CAA GCA GCA AG-3') and 3CS (5'-AAG CAG ACT TGA CCT GA-3') in combination with IMP and VIM primers, respectively. Two different amplicons per isolate were sequenced in an overlapping fashion to ensure that the entire MBL gene allele was obtained. Automated sequencing was performed on the PCR products with an ABI Prism 3100 genetic analyzer (Applied Biosystems, Norwalk, CT) as previously described, using Sequence Analysis software (9).
PFGE. Pulsed-field gel electrophoresis (PFGE) was performed on the CR isolates by using a modification of two different protocols, previously described for Streptococcus pneumoniae (11) and Stenotrophomas maltophilia (2).
A single isolated colony of P. aeruginosa was inoculated into 2 ml brain heart infusion broth (PML Microbiologicals, Wilsonville, OR) and incubated for 16 to 18 h at 37°C. A 150- to 180-µl aliquot of the overnight culture was transferred to a 1.5-ml microcentrifuge tube, and cells were harvested by centrifugation. Following aspiration of the supernatant, the cell pellet was resuspended in 150 µl PIV buffer (10 mM Tris-HCl [pH 8.0], 1 mM NaCl). An equal volume of molten 1.6% low-melting-point agarose (Bio-Rad Laboratories, Hercules, CA) was added to the cell suspension, mixed thoroughly by pipetting, and then immediately cast into plug molds (Bio-Rad Laboratories, Hercules, CA), which were placed at 4°C for at least 10 min to allow plugs to completely solidify. Plugs were then transferred to 50-ml tubes containing 5 ml freshly prepared lysis buffer (6 mM Tris-HCl [pH 8.0], 1 M NaCl, 0.5% polyoxyethylene 20 cetyl ether, 0.2% deoxycholic acid, 0.5% N-lauroylsarcosine, 1 mg/ml lysozyme, 20 µg/ml RNaseA) (Sigma-Aldrich, St. Louis, MO). Plugs were incubated in lysis buffer in a 37°C water bath for 2 h, and the lysis buffer was then removed and replaced with 5 ml freshly prepared ESP buffer (0.5 M EDTA [pH 9.0], 1% N-lauroylsarcosine, 0.1 mg/ml proteinase K) (Roche Diagnostics, Laval, Quebec, Canada). Plugs were incubated in ESP buffer in a 56°C water bath for 2 to 20 h. Following incubation, ESP buffer was removed, and plugs were rinsed and washed in TE buffer (10 mM Tris-HCl [pH 8.0], 0.1 mM EDTA [pH 9.0]).
Pseudomonas aeruginosa agarose plugs were digested with SpeI (Roche Diagnostics, Laval, Quebec, Canada); a reference strain, Salmonella enterica serovar Braenderup H9812, was digested with XbaI (New England Biolabs) and used as an electrophoresis molecular weight marker (7). Briefly, an agarose plug was sliced into thirds; one-third of the plug was transferred to a microcentrifuge tube and equilibrated in 150 µl of 1x restriction enzyme (RE) buffer at 37°C for at least 10 min. Following equilibration, RE buffer was removed and replaced with 100 µl of RE buffer containing either 30 U of SpeI enzyme (P. aeruginosa) or 40 U of XbaI (Salmonella serovar Braenderup H9812 reference strain). SpeI and XbaI digestion mixes were incubated at 37°C. Following SpeI digestion, the buffer was aspirated, and digested plugs were briefly melted at 65°C prior to being loaded into a 1% pulsed-field-certified agarose (Bio-Rad Laboratories, Hercules, CA) gel using ART 200G (Molecular BioProducts, San Diego, CA) wide-bore pipette tips; XbaI-digested reference strain Salmonella serovar Braenderup H9812 plugs were loaded directly into the gel. Electrophoresis was performed on a CHEF MAPPER XA apparatus (Bio-Rad Laboratories, Hercules, CA) at 14°C for 18 h under the following conditions: initial switch time, 5.3 s; final switch time, 34.9 s; included angle, 120°; voltage gradient, 6 V/cm; ramping factor, linear. Gels were stained with ethidium bromide and destained with distilled water prior to illumination under UV light. Images were captured with Quantity One software (Bio-Rad Laboratories, Hercules, CA).
Gel images in TIFF format were exported to BioNumerics software, version 3.0 (Applied Maths, Sint-Martens-Latem, Belgium), for analysis. Comparisons for P. aeruginosa were made using the band-based Dice coefficient, which is a binary coefficient measuring similarity based upon common and different bands. Dendrograms were generated using the unweighted-pair group method using average linkages, with a 1.5% position tolerance. DNA relatedness was calculated based on the Dice coefficient, and isolates were considered genetically related if the Dice coefficient correlation was 80% or greater, which corresponds to the "possibly related (4 to 6 bands difference)" criterion of Tenover et al. (23).
|
|
|---|
Antimicrobial susceptibility. Of the 518 clinical and 10 environmental CR P. aeruginosa isolates included in this study, 47 (9%) were resistant to PIP, 181 (34%) were resistant to CAZ, 228 (43%) were resistant to TOB, 326 (62%) were resistant to GEN, and 258 (49%) were resistant to CIP (Table 1). The isolates producing MBLs were more resistant to PIP, CAZ, GEN, TOB, and CIP than were CR isolates not producing MBLs (Table 1). Additional antimicrobial susceptibility testing was performed on the MBL-positive isolates and showed resistance to ATM in 16% of isolates and to AMK in 80% of isolates. No COL resistance was detected among the MBL producers (Table 1). Paterson recently suggested definitions for multidrug-resistant and panresistant P. aeruginosa (13); all of the MBL-producing isolates and 52% of the CR isolates not producing MBLs were multidrug resistant, while 11% of the MBL-producing isolates and 8% of the CR isolates not producing MBLs were panresistant.
|
View this table: [in a new window] |
TABLE 1. Resistance rates for clinical and environmental isolates of CR Pseudomonas aeruginosa isolated in the Calgary Health Region during 2002-2006
|
Pulsed-field gel electrophoresis. PFGE revealed two closely related restriction patterns (clusters MBLV [154 isolates] and MBLVR [related to MBLV] [21 isolates]) for the 178 VIM-2-producing isolates (Fig. 1). The remaining three VIM-2-producing strains were not related to these clusters or to each other. The majority (96/154 [62%]) of the strains belonging to cluster MBLV were isolated from patients admitted to acute care center I, 7/154 (4%) strains were isolated from acute care center II, 16/154 (10%) strains were isolated from acute care center III, 14/154 (9%) were isolated from nursing homes, and 11 (7%) were isolated from patients at community care centers. The remaining 10 isolates that belonged to cluster MBLV were recovered from contaminated faucets at the ICU and the bone marrow transplant unit of acute care center I. Of the 48 patients with cluster MBLV strains that received medical care outside acute care center I, 42 (88%) were transferred or discharged from acute care center I. An increased number of MBLV strains were isolated during April 2003 to June 2004 and again from January to April 2006 (Fig. 2).
![]() View larger version (86K): [in a new window] |
FIG. 1. PFGE patterns and dendrogram of MBL-producing P. aeruginosa strains isolated from the Calgary Health Region during April 2002 to March 2006. The dendrogram was constructed by cluster analysis using Bionumerics software (version 3.0). Percentages of similarity are shown above the dendrogram. MBLV and MBLVR (related to V) strains produced VIM-2, and MBLI (producing IMP-7) and NMBL (MBL negative) indicate clusters with >80% homology. P01, patient isolate 01, etc.; E01, environmental isolate 01, etc.; ACCI, acute care center I; ACCII, acute care center II; ACCIII, acute care center III; NH, nursing home; CCC, community care center. These isolates were randomly selected to show the separation of DNA fragments.
|
![]() View larger version (18K): [in a new window] |
FIG. 2. Distribution of MBL-producing P. aeruginosa strains isolated in the Calgary Health Region during April 2002 to March 2006. MBLV, cluster producing VIM-2; MBLVR, cluster related to MBLV, producing VIM-2; MBLI, cluster producing IMP-7; AJ, April to June; JS, July to September; OD, October to December; JM, January to March; -02 to -06, 2002 to 2006, respectively. The arrow denotes the replacement of faucets at acute care center I.
|
The IMP-7-producing isolates (n = 7) belonged to a different cluster (MBLI) and were related to the strains described during an outbreak in the 1990s (6). Strains belonging to this cluster were isolated sporadically during the 4-year study period.
One hundred forty-four isolates that were CR but tested negative for MBLs were available for PFGE. Typing of these isolates showed the following patterns: 53/144 were closely related (cluster NMBL) (Fig. 1), 4/144 belonged to cluster MBLV, 1/144 belonged to cluster MBLVR, 3/144 belonged to cluster MBLI, and the remaining 83 were not related to any of the clusters or to each other. The majority (27/53 [51%]) of strains belonging to cluster NMBL were isolated from patients admitted to acute care center II, 13/53 (25%) were isolated from acute care center I, 5/53 (9%) were isolated from acute care center II, 5/53 (9%) were isolated from nursing homes, and 3 (6%) were submitted from community care centers. Of the 26 patients with cluster NMBL strains that received medical care outside acute care center II, 8 (31%) were transferred from or were in contact with acute care center II.
|
|
|---|
The molecular epidemiology of MBL-producing P. aeruginosa strains on a regional or countrywide scale has been described previously for Poland (4), Greece (5), Italy (17, 24), and Japan (8). These studies consisted of typing of MBL-producing P. aeruginosa strains and the identification of integron-associated gene cassettes collected from different parts of the respective countries over specific periods of time ranging from 1 month to 3 years. The majority of these studies have shown that the emergence of MBL-producing P. aeruginosa strains (especially VIM-2-producing strains) occurs simultaneously and seemingly independently in different parts of the respective countries. The situation in Canada is very different in that MBL-producing bacteria have only been described for the Calgary Health Region (6, 9) and do not seem to be present in other parts of the country. Our study describes the molecular epidemiology of CR P. aeruginosa in a large, well-defined geographical region over a 4-year period. We studied all of the MBL-producing isolates as well as a portion of the non-MBL-producing isolates collected in the Calgary Health Region during that period. We identified the class 1 integron-associated gene cassettes in a small number of VIM-2-producing isolates, which had striking similarities to integron-associated structures previously described for VIM-2-producing P. aeruginosa strains from Portugal (16). This suggests that the emergence of VIM-2-producing P. aeruginosa occurs independently in different parts of the world.
Molecular typing of VIM-2-producing P. aeruginosa strains showed that clonally related strains (cluster MBLV) were responsible for a nosocomial outbreak in the ICU of acute care center I during April to December 2003 (Fig. 2). This cluster then spread to the bone marrow transplant unit and caused a similar outbreak during January to May 2004. Environmental strains isolated from faucets in both of these units also belonged to cluster MBLV (Fig. 1). This outbreak was contained with strict contact isolation practices and the replacement of faucets at both of the units (arrow in Fig. 2). An increase in the number of newly infected patients with clusters MBLV and MBLVR occurred during January and February 2006 at acute care center I (Fig. 2). This was the first appearance of MBLVR at acute care center I. These cases originated from different wards and units, and strict isolation and barrier precautions prevented a large-scale outbreak at this institution, underscoring the importance of infection control practices and continuous molecular surveillance of MBL-producing organisms.
Molecular typing further illustrated the ease with which VIM-2-producing strains from cluster MBLV accompanied patients transferred to other acute care centers, nursing homes, or the community. However, these strains did not cause an outbreak outside acute care center I, underlining yet again the importance of environmental reservoirs as a cause of nosocomial outbreaks due to P. aeruginosa (3). Typing also showed that three clusters were present at the different adult acute care centers within the Calgary Health Region. Of particular interest is the fact that MBL-producing P. aeruginosa strains have not been isolated from patients in the pediatric hospital. Cluster MBLI, which was responsible for a nosocomial outbreak at acute care center I during the late 1990s, practically disappeared during the study period, being replaced by cluster MBLV. Strains from clusters MBLV and MBLVR have nearly identical susceptibility profiles to that of cluster MBLI strains and share the aacC1 gene cassette, but they behave differently since infections caused by MBLV and MBLVR strains were associated with a higher case fatality rate and invasive disease (9). In our previous population-based study, we described the MBLA, MBLAR, and MBLB clusters. There is some overlap with the present study, as cluster MBLV is the same as MBLA, MBLVR is the same as MBLAR, and MBLI is the same as MBLB. Future investigations, including the study of microbiological and ecological factors that make MBLV such a successful pathogen, will hopefully provide some insight into these interesting issues. Our findings suggest that the spread and dissemination of MBL clusters among P. aeruginosa populations in large geographic healthcare regions are dynamic processes that require continuous molecular surveillance.
This study was funded by the Antibiotic Resistant Organism (ARO) Research fund, which is sponsored by a partnership between Calgary Laboratory Services, the Calgary Health Trust, the University of Calgary, and the Calgary Health Region.
Published ahead of print on 22 November 2006. ![]()
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»